Project acronym MIX2FIX
Project Hybrid, organic-inorganic chalcogenide optoelectronics
Researcher (PI) Thomas STERGIOPOULOS
Host Institution (HI) ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Country Greece
Call Details Consolidator Grant (CoG), PE8, ERC-2018-COG
Summary The new generation of optoelectronics seeks for emerging semiconductors which combine high performance with low cost. Lead halide organic-inorganic perovskites manifest as excellent optoelectronic materials for this purpose, but at the expense of robustness and environmental compatibility. This presents a major challenge which this research addresses directly. Viable alternatives have to be identified. To tackle this challenge, MIX2FIX proposes to develop a new class of solution-processable optoelectronic devices based on air-stable, non-toxic metal chalcogenides endowed with an organic part, which will facilitate solution-processing and potentially enrich the compounds with the spectacular properties of halide perovskites. To achieve this, the CoG project has set the following objectives: (i) designing and developing optoelectronically-active, organic-inorganic chalcogenide thin films that have never been explored before, by mimicking strategies from established perovskite technology, (ii) devising means to improve their optoelectronic quality so as to be comparable with the best single-crystal semiconductors and (iii) implementing optimized materials into boundary-pushing PV and LED devices. Addressing these objectives will enable the development of novel functional hybrids at the boundaries of perovskite and chalcogenide thin films. With this, optoelectronics with efficiency and stability, comparable or higher than those of lead halide perovskite or chalcopyrite devices, will be demonstrated. This project will therefore permit the transition for emerging optoelectronic materials from toxic lead halide perovskites to green hybrid chalcogenides. Consolidating this unproven but disruptive technology will secure sustainable future for other areas of interest beyond photovoltaics, displays and lighting such as in X-Rays detectors and phototransistors or even beyond optoelectronics, in systems such as batteries and supercapacitors.
Summary
The new generation of optoelectronics seeks for emerging semiconductors which combine high performance with low cost. Lead halide organic-inorganic perovskites manifest as excellent optoelectronic materials for this purpose, but at the expense of robustness and environmental compatibility. This presents a major challenge which this research addresses directly. Viable alternatives have to be identified. To tackle this challenge, MIX2FIX proposes to develop a new class of solution-processable optoelectronic devices based on air-stable, non-toxic metal chalcogenides endowed with an organic part, which will facilitate solution-processing and potentially enrich the compounds with the spectacular properties of halide perovskites. To achieve this, the CoG project has set the following objectives: (i) designing and developing optoelectronically-active, organic-inorganic chalcogenide thin films that have never been explored before, by mimicking strategies from established perovskite technology, (ii) devising means to improve their optoelectronic quality so as to be comparable with the best single-crystal semiconductors and (iii) implementing optimized materials into boundary-pushing PV and LED devices. Addressing these objectives will enable the development of novel functional hybrids at the boundaries of perovskite and chalcogenide thin films. With this, optoelectronics with efficiency and stability, comparable or higher than those of lead halide perovskite or chalcopyrite devices, will be demonstrated. This project will therefore permit the transition for emerging optoelectronic materials from toxic lead halide perovskites to green hybrid chalcogenides. Consolidating this unproven but disruptive technology will secure sustainable future for other areas of interest beyond photovoltaics, displays and lighting such as in X-Rays detectors and phototransistors or even beyond optoelectronics, in systems such as batteries and supercapacitors.
Max ERC Funding
2 731 250 €
Duration
Start date: 2019-09-01, End date: 2024-08-31
Project acronym ProMiDis
Project A unified drug discovery platform for protein misfolding diseases
Researcher (PI) Georgios SKRETAS
Host Institution (HI) ETHNIKO IDRYMA EREVNON
Country Greece
Call Details Consolidator Grant (CoG), LS9, ERC-2018-COG
Summary It is now widely recognized that a variety of major diseases, such as Alzheimer’s disease, Huntington’s disease, systemic amyloidosis, cystic fibrosis, type 2 diabetes etc., are characterized by a common molecular origin: the misfolding of specific proteins. These disorders have been termed protein misfolding diseases (PMDs) and the vast majority of them remain incurable. Here, I propose the development of a unified approach for the discovery of potential therapeutics against PMDs. I will generate engineered bacterial cells that function as a broadly applicable discovery platform for compounds that rescue the misfolding of PMD-associated proteins (MisPs). These compounds will be selected from libraries of drug-like molecules biosynthesized in engineered bacteria using a technology that allows the facile production of billions of different test molecules. These libraries will then be screened in the same bacterial cells that produce them and the rare molecules that rescue MisP misfolding effectively will be selected using an ultrahigh-throughput genetic screen. The effect of the selected compounds on MisP folding will then be evaluated by biochemical and biophysical methods, while their ability to inhibit MisP-induced pathogenicity will be tested in appropriate mammalian cell assays and in established animal models of the associated PMD. The molecules that rescue the misfolding of the target MisPs and antagonize their associated pathogenicity both in vitro and in vivo, will become drug candidates against the corresponding diseases. This procedure will be applied for different MisPs to identify potential therapeutics for four major PMDs: Huntington’s disease, cardiotoxic light chain amyloidosis, dialysis-related amyloidosis and retinitis pigmentosa. Successful realization of ProMiDis will provide invaluable therapeutic leads against major diseases and a unified framework for anti-PMD drug discovery.
Summary
It is now widely recognized that a variety of major diseases, such as Alzheimer’s disease, Huntington’s disease, systemic amyloidosis, cystic fibrosis, type 2 diabetes etc., are characterized by a common molecular origin: the misfolding of specific proteins. These disorders have been termed protein misfolding diseases (PMDs) and the vast majority of them remain incurable. Here, I propose the development of a unified approach for the discovery of potential therapeutics against PMDs. I will generate engineered bacterial cells that function as a broadly applicable discovery platform for compounds that rescue the misfolding of PMD-associated proteins (MisPs). These compounds will be selected from libraries of drug-like molecules biosynthesized in engineered bacteria using a technology that allows the facile production of billions of different test molecules. These libraries will then be screened in the same bacterial cells that produce them and the rare molecules that rescue MisP misfolding effectively will be selected using an ultrahigh-throughput genetic screen. The effect of the selected compounds on MisP folding will then be evaluated by biochemical and biophysical methods, while their ability to inhibit MisP-induced pathogenicity will be tested in appropriate mammalian cell assays and in established animal models of the associated PMD. The molecules that rescue the misfolding of the target MisPs and antagonize their associated pathogenicity both in vitro and in vivo, will become drug candidates against the corresponding diseases. This procedure will be applied for different MisPs to identify potential therapeutics for four major PMDs: Huntington’s disease, cardiotoxic light chain amyloidosis, dialysis-related amyloidosis and retinitis pigmentosa. Successful realization of ProMiDis will provide invaluable therapeutic leads against major diseases and a unified framework for anti-PMD drug discovery.
Max ERC Funding
1 972 000 €
Duration
Start date: 2019-03-01, End date: 2024-02-29
